Comunicados de prensa de Regeneron Pharmaceuticals

Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the placeb…

Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment

Pasatru is the first and only FDA -approved treatment demonstrating reductions in both new HO lesions and clinician-assessed flare-ups, per results of a 56-week placebo-controlled trial in adults with…

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation

LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy

In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-actin…

TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2026 financial and operating results on Friday…

FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval base…

Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31, 2026…

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion EYLEA HD ® U…

LOS ANGELES, July 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regeneron Pharmaceuticals, Inc., (“Regeneron” or the "Company") (NASDAQ: REGN) investors of a class action on behalf of inve…

Regeneron Sued for Fraud Over Misrepresentations about its Clinical Trials – Investors Notified to Contact BFA Law

San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Regeneron Therapeuti…

TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursda…

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE)…

Commvault Systems (NASDAQ: CVLT); MongoDB (NASDAQ: MDB); New Era Energy & Digital (NASDAQ: NUAI); and Regeneron Pharmaceuticals (NASDAQ: REGN) Shareholders